179 related articles for article (PubMed ID: 18249125)
1. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer.
Kumar SK; Roy I; Anchoori RK; Fazli S; Maitra A; Beachy PA; Khan SR
Bioorg Med Chem; 2008 Mar; 16(6):2764-8. PubMed ID: 18249125
[TBL] [Abstract][Full Text] [Related]
2. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
3. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells.
Levitt RJ; Zhao Y; Blouin MJ; Pollak M
Cancer Lett; 2007 Oct; 255(2):300-6. PubMed ID: 17602833
[TBL] [Abstract][Full Text] [Related]
4. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of inhibitors of Hedgehog signaling based on the alkaloid cyclopamine.
Winkler JD; Isaacs A; Holderbaum L; Tatard V; Dahmane N
Org Lett; 2009 Jul; 11(13):2824-7. PubMed ID: 19552464
[TBL] [Abstract][Full Text] [Related]
6. Cyclopamine bioactivity by extraction method from Veratrum californicum.
Turner MW; Cruz R; Mattos J; Baughman N; Elwell J; Fothergill J; Nielsen A; Brookhouse J; Bartlett A; Malek P; Pu X; King MD; McDougal OM
Bioorg Med Chem; 2016 Aug; 24(16):3752-7. PubMed ID: 27338657
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R
Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697
[TBL] [Abstract][Full Text] [Related]
8. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
9. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.
Mhaka A; Denmeade SR; Yao W; Isaacs JT; Khan SR
Bioorg Med Chem Lett; 2002 Sep; 12(17):2459-61. PubMed ID: 12161157
[TBL] [Abstract][Full Text] [Related]
10. Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.
Balbous A; Renoux B; Cortes U; Milin S; Guilloteau K; Legigan T; Rivet P; Boissonnade O; Martin S; Tripiana C; Wager M; Bensadoun RJ; Papot S; Karayan-Tapon L
Mol Cancer Ther; 2014 Sep; 13(9):2159-69. PubMed ID: 25053823
[TBL] [Abstract][Full Text] [Related]
11. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
12. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
13. Tumor shrinkage by cyclopamine tartrate through inhibiting hedgehog signaling.
Fan Q; Gu D; He M; Liu H; Sheng T; Xie G; Li CX; Zhang X; Wainwright B; Garrossian A; Garrossian M; Gardner D; Xie J
Chin J Cancer; 2011 Jul; 30(7):472-81. PubMed ID: 21718593
[TBL] [Abstract][Full Text] [Related]
14. One Hundred Faces of Cyclopamine.
Iovine V; Mori M; Calcaterra A; Berardozzi S; Botta B
Curr Pharm Des; 2016; 22(12):1658-81. PubMed ID: 26759083
[TBL] [Abstract][Full Text] [Related]
15. Cyclopamine functions as a suppressor of benign prostatic hyperplasia by inhibiting epithelial and stromal cell proliferation via suppression of the Hedgehog signaling pathway.
Yuan YF; Zhu WX; Liu T; He JQ; Zhou Q; Zhou X; Zhang X; Yang J
Int J Mol Med; 2020 Jul; 46(1):311-319. PubMed ID: 32319534
[TBL] [Abstract][Full Text] [Related]
16. I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs.
Chen JK
Nat Prod Rep; 2016 May; 33(5):595-601. PubMed ID: 26787175
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog antagonist cyclopamine isomerizes to less potent forms when acidified.
Wilson SR; Strand MF; Krapp A; Rise F; Petersen D; Krauss S
J Pharm Biomed Anal; 2010 Sep; 52(5):707-13. PubMed ID: 20236786
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
19. Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.
Peluso MO; Campbell VT; Harari JA; Tibbitts TT; Proctor JL; Whitebread N; Conley JM; White KF; Kutok JL; Read MA; McGovern K; Faia KL
PLoS One; 2014; 9(3):e90534. PubMed ID: 24608250
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
Tremblay MR; Lescarbeau A; Grogan MJ; Tan E; Lin G; Austad BC; Yu LC; Behnke ML; Nair SJ; Hagel M; White K; Conley J; Manna JD; Alvarez-Diez TM; Hoyt J; Woodward CN; Sydor JR; Pink M; MacDougall J; Campbell MJ; Cushing J; Ferguson J; Curtis MS; McGovern K; Read MA; Palombella VJ; Adams J; Castro AC
J Med Chem; 2009 Jul; 52(14):4400-18. PubMed ID: 19522463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
